Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer.

ABSTRACT:

Introduction

Enzalutamide is an oral androgen receptor (AR) signaling inhibitor that was specifically engineered to overcome castration-resistant prostate cancer (CRPC) harboring AR amplification or overexpression. Enzalutamide has demonstrated significant activity in men with metastatic CRPC.

Aims

To update the evidence and provide an overview of the available data on enzalutamide.

Evidence review

Peer reviewed articles published and listed in Medline Search were reviewed. In addition, relevant ASCO and ESMO abstracts were searched. The activity of enzalutamide is mediated by potently antagonizing the full-length AR, impairing translocation of the AR from the cytoplasm into the nucleus, and inhibiting the transcriptional activity of the AR by modulating the interacti

SUBMITTER: Golshayan AR 

PROVIDER: S-EPMC3622394 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature